Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration Clinical Trial
Official title:
A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration
Primary Objectives:
To assess the efficacy of intravitreal administered Eylea in preventing visual loss in
subjects with a retinal pigment epithelial detachment (PED) subtype of neovascular
age-related macular degeneration (AMD) measured by mean change in BCVA at Month 12 compared
to Baseline.
Secondary Objectives:
1. To assess the safety and tolerability of repeated intravitreal administration of Eylea
in subjects with the PED subtype of neovascular AMD for a period of 1 year
2. To assess the effect of repeated intravitreal administration of Eylea on Central
Subfield Thickness (CSFT), Central Subfield Volume (CSFV), and PED height and volume.
3. To assess the effect of repeated intravitreal administration of Eylea on vision related
quality of life in subjects with PED study type of neovascular AMD assessed using the
NEI/VFQ-25 questionnaire
n/a